Clinical trial
Targeted AntiBiotics for Chronic Pulmonary Disease: Can Targeted Antibiotic Therapy Improve the Prognosis of Pseudomonas Aeruginosa Infected Patients With Chronic Pulmonary Obstructive Disease, Non-cystic Fibrosis Bronchiectasis and Asthma? A Multicenter, Randomized, Controlled, Open-label Trial.
NCT03262142 is registered in ClinicalTrials.gov with Chronic Obstructive Pulmonary Disease Trial Network, Denmark as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Targeted AntiBiotics for Chronic Pulmonary Disease: Can Targeted Antibiotic Therapy Improve the Prognosis of Pseudomonas Aeruginosa Infected Patients With Chronic Pulmonary Obstructive Disease, Non-cystic Fibrosis Bronchiectasis and Asthma? A Multicenter, Randomized, Controlled, Open-label Trial.
- Lead sponsor
- Chronic Obstructive Pulmonary Disease Trial Network, Denmark
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- January 10, 2018
- Completion date
- March 1, 2023
- Enrollment
- 51 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
asthma, bronchiectasis, copd, pseudomonas aeruginosa, respiratory tract infections